BERLIN, June 5, 2009 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today announced a 68% overall response rate in patients with immune thrombocytopenic purpura (ITP) treated with low doses of veltuzumab, administered either intravenously or subcutaneously. Results from this multicenter, open-label, single-arm, Phase I/II study were presented at the 14th Congress of the European Hematology Association.
